Electrophoretic mobility shift assay for NF-κB (arrow) in the cultured human THP-1 cell line

<p><b>Copyright information:</b></p><p>Taken from "Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line"</p><p>Arthritis Research & Therapy 2005;7(5):R1124-R1132.</p><p>Published online 21 Jul 2005</p><p>PMCID:PMC1257440.</p><p>Copyright © 2005 Cutolo et al.; licensee BioMed Central Ltd.</p> Electrophoretic mobility shift assay for NF-κB (arrow) in the cultured human THP-1 cell line after 168 hours of hormonal treatment and without or with staurosporine (17 nM) reveals an increased DNA binding in 17β-oestradiol (E2)-treated cells. Super shift assay for p65 (arrow) in the cells under the same conditions confirms the increased binding of p65 in E2-treated cells. The results are representative of four separate experiments. cnt, control; T, testosterone

NF-κB p65, IκB-α and phosphorylated IκB-α (ser 32) protein expression in the cultured human THP-1 cell line after 168 hours of hormonal treatment without or with staurosporine

<p><b>Copyright information:</b></p><p>Taken from "Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line"</p><p>Arthritis Research & Therapy 2005;7(5):R1124-R1132.</p><p>Published online 21 Jul 2005</p><p>PMCID:PMC1257440.</p><p>Copyright © 2005 Cutolo et al.; licensee BioMed Central Ltd.</p> The results are representative of four separate experiments. CNT, control; T, testosterone; E2, 17β-oestradiol

Growth rate of the cultured human THP-1 cell line without or with 17β-oestradiol (E2) and testosterone (T), and with staurosporine after 168 hours

<p><b>Copyright information:</b></p><p>Taken from "Sex hormone modulation of cell growth and apoptosis of the human monocytic/macrophage cell line"</p><p>Arthritis Research & Therapy 2005;7(5):R1124-R1132.</p><p>Published online 21 Jul 2005</p><p>PMCID:PMC1257440.</p><p>Copyright © 2005 Cutolo et al.; licensee BioMed Central Ltd.</p> The number of recovered live cells at different times was evaluated using the methyl tetrazolium salt reduction test. Results are expressed as the mean ± standard deviation of five different experiments

The table describes patients’ clinical characteristics, starting from personal data (age and gender), disease specific characteristics (disease subtype in percentages, autoantibody positivity in percentages, Raynaud’s phenomenon and disease durations, general digital ulcer incidence and according to pattern of microangiopathy).

<p>The table describes patients’ clinical characteristics, starting from personal data (age and gender), disease specific characteristics (disease subtype in percentages, autoantibody positivity in percentages, Raynaud’s phenomenon and disease durations, general digital ulcer incidence and according to pattern of microangiopathy).</p

In the left part of the table DXA scan parameters average values in all patients population are shown.

<p>In the right part of the table there are p values for correlation of DXA scan data with 25(OH)D serum levels and with glucocorticoid therapy.</p

25(OH)D serum levels and significant correlations.

<p>A) Average 25(OH)D serum concentrations in all seasons: a statistically significant difference was observed among seasonal 25(OH)D serum concentrations (p = 0.032). The Dunn’s multiple comparison post-test shows a more significant difference between patients observed in winter compared to summer months (p = 0.0086). B) Average 25(OH)D serum concentrations in patients showing presence/absence of bi-basal fibrotic changes at lung CT scan: a statistically significant difference was found between 25(OH)D serum concentrations in patients showing presence vs absence of bi-basal fibrotic changes at lung CT scan (p = 0.04). C) Medsger’s disease severity scale “peripheral vascular” parameter correlation with 25(OH)D serum concentrations (p = 0.03).D) Medsger’s disease severity scale “kidney” parameter correlation with 25(OH)D serum concentrations (p = 0.02). E) Medsger’s disease severity scale “gastro-intestinal” parameter correlation with 25(OH)D serum concentrations (p = 0.05).</p

The table describes organ involvement in patients population as assessed through laboratory (creatinine levels) and instrumental parameters: Average pulmonary function test measurements (DLCO%, FVC% and FVC%/DLCO% ratio), average echocardiographic estimation of SPAP values, patients percentage showing interstitial lung disease or bi-basal fibrotic changes at lung CT scan, patients percentage showing enlarged hearth at chest X-rays, patients percentage showing ECG alterations (conduction disorders and arrhythmias), patients percentage for each nailfold videocapillaroscopic pattern.

<p>The table describes organ involvement in patients population as assessed through laboratory (creatinine levels) and instrumental parameters: Average pulmonary function test measurements (DLCO%, FVC% and FVC%/DLCO% ratio), average echocardiographic estimation of SPAP values, patients percentage showing interstitial lung disease or bi-basal fibrotic changes at lung CT scan, patients percentage showing enlarged hearth at chest X-rays, patients percentage showing ECG alterations (conduction disorders and arrhythmias), patients percentage for each nailfold videocapillaroscopic pattern.</p

25(OH)D serum concentrations and treatment.

<p>25(OH)D serum concentrations compared in patients assuming/not assuming supplementation with 1,000 IU daily for at least 6–12 months. There was no influence of treatments with oral colecalciferol on 25(OH)D serum concentrations: 18.8 ±10 ng/ml in treated and 18.7 ±9 ng/ml in untreated patients (p = 0.81).</p

Medsger’s disease severity scale (DSS) parameters in the study population.

<p>In the left part of the figure, a graphic representation describes organ involvement through the distribution of the five values (0 to 4) for each parameter of Medsger’s DSS (white = none, light grey = mild, intermediate grey = moderate, dark grey = severe, black = end-stage). In the right part of the figure the same distribution is described in percentages (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = end-stage).</p